Security
Polaryx Therapeutics, Inc. Common Stock · PLYX
PLYXNASDAQCommon stockCurrentCIK 2075320Updated Oct 6, 2026
PLYX price & chart
Loading TradingView…
NASDAQ:PLYX on TradingView ↗About the company
We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our small molecule drug candidates share target indications, as well as similar modes of action, that have been demonstrated to address lysosomal dysfunction, neuroinflammation, and neuronal loss in our validated animal models that closely mimic human clinical phenotypes. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch a Phase 2 proof-of-concept basket trial which may enhance PLX-200’s potential to become the standard of care across multiple LSDs. Our drug candidate pipeline includes:
In the news
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference ↗
Recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
ARS filing
DEFA14A filing
Show 5 more recent filings
DEF 14A filing
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Shareholder Director Nominations · Other Events
Items 5.08, 8.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| AssetsUSD | 11,812,000Source | — | 3,502,000Source | — | 5,170,000Source | 5,001,000Source |
| Current assets: | ||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,542,000Source | — | 3,080,000Source | — | 5,143,000Source | 4,621,000Source |
| Assets, CurrentUSD | 11,812,000Source | — | 3,502,000Source | — | 5,170,000Source | 5,001,000Source |
| LIABILITIES AND EQUITY | ||||||
| LiabilitiesUSD | 873,000Source | — | 1,014,000Source | — | 605,000Source | 289,000Source |
| Stockholders’ equity: | ||||||
| Common Stock, Value, IssuedUSD | 5,000Source | — | 5,000Source | — | 5,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 114,493,000Source | — | 104,662,000Source | — | 104,195,000Source | 95,358,000Source |
| Retained Earnings (Accumulated Deficit)USD | -103,559,000Source | — | -102,179,000Source | — | -99,635,000Source | -90,650,000Source |
| Stockholders' Equity Attributable to ParentUSD | 10,939,000Source | 3,246,000Source | 2,488,000Source | 4,254,000Source | 4,565,000Source | 4,712,000Source |
| Liabilities and EquityUSD | 11,812,000Source | — | 3,502,000Source | — | 5,170,000Source | 5,001,000Source |
| Current liabilities: | ||||||
| Liabilities, CurrentUSD | 873,000Source | — | 1,014,000Source | — | 605,000Source | 289,000Source |
| Accounts Payable, CurrentUSD | 683,000Source | — | 850,000Source | — | 470,000Source | 72,000Source |
| Additional Financial Items | ||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | 250,000Source | 467,000Source |
| Accrued Liabilities, Current | —Source | — | —Source | — | — | — |
cash flow · annual statements
| Line item | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 467,000Source | 4,451,000Source | 4,725,000Source | 2,400,000Source |
| Changes in operating assets and liabilities: | ||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | 380,000Source | -17,000Source | 398,000Source | -401,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | -2,063,000Source | -709,000Source | -3,944,000Source | -2,573,000Source |
| Cash flows from financing activities: | ||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | 250,000Source | 4,466,000Source | 7,192,000Source |
| Additional Financial Items | ||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 467,000Source | — | 0Source | 2,300,000Source |
| General and Administrative ExpenseUSD | 661,000Source | 408,000Source | 1,279,000Source | 336,000Source | 1,555,000Source | 1,541,000Source |
| Net Income (Loss) Attributable to ParentUSD | -1,380,000Source | -1,008,000Source | -2,544,000Source | -5,052,000Source | -8,985,000Source | -30,356,000Source |
| Operating ExpensesUSD | 1,380,000Source | 884,000Source | 1,958,000Source | 5,052,000Source | 7,821,000Source | 4,352,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 250,000Source | 4,493,000Source | 7,320,000Source |
| Net Income (Loss) Available to Common Stockholders, Basic | —Source | —Source | —Source | —Source | — | — |
income statement · annual statements
| Line item | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | -1,380,000Source | -884,000Source | -1,958,000Source | -5,052,000Source | -7,821,000Source | -4,352,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | -8,985,000Source | -30,356,000Source |
| Net Income (Loss) Attributable to ParentUSD | -1,380,000Source | -1,008,000Source | -2,544,000Source | -5,052,000Source | -8,985,000Source | -30,356,000Source |
| Earnings Per Share, BasicUSD per share | -0.03Source | -0.02Source | -0.05Source | -0.11Source | -0.2Source | -0.89Source |
| Earnings Per Share, DilutedUSD per share | -0.03Source | -0.02Source | -0.05Source | -0.11Source | -0.2Source | -0.89Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 48,278,370Source | 44,670,601Source | 47,219,329Source | 44,338,960Source | 45,422,581Source | 34,200,660Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 48,278,370Source | 44,670,601Source | 47,219,329Source | 44,338,960Source | 45,422,581Source | 34,200,660Source |
| Additional Financial Items | ||||||
| General and Administrative ExpenseUSD | 661,000Source | 408,000Source | 1,279,000Source | 336,000Source | 1,555,000Source | 1,541,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | -8,985,000Source | -30,356,000Source |
| Operating ExpensesUSD | 1,380,000Source | 884,000Source | 1,958,000Source | 5,052,000Source | 7,821,000Source | 4,352,000Source |
| Research and Development ExpenseUSD | 719,000Source | 476,000Source | 679,000Source | 4,716,000Source | 6,266,000Source | 2,811,000Source |
| Net Income (Loss) Available to Common Stockholders, Basic | —Source | —Source | —Source | —Source | — | — |
Offerings
Registration 333-291681
- Offering price
- market-price
- Ticker
- PLYX
Filing attachments
ea030392801ex99-1.htm · 8-K · 2026-09-01
Exhibit 99.1 Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles Appointment further strengthens clinical leadership and execution capabilities ahead of planned SOTERIA Phase 2 initiation in Q4 2026 PARAMUS, N.J., September 1, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company deve…
Read attachment ↗ea029169201ex99-1.htm · 8-K · 2026-05-28
EX-99.1 3 ea029169201ex99-1.htm PRESS RELEASE DATED MAY 28, 2026 Exhibit 99.1 Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced …
Read attachment ↗ea027550001ex99-1_polaryx.htm · SCHEDULE 13D · 2026-02-05
Exhibit 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common stock, par value $0.0001 per share, of Polaryx Therapeutics, Inc. and further agree that this Joint Filing Agreement shall be included as an exhibit to such j…
Read attachment ↗